Rein Therapeutics ("Rein") , formerly known as Aileron Therapeutics, Inc. ("Aileron") , a biopharmaceutical company advancing a ...

Quanta receives US FDA clearance to begin phase 1 trial of QTX3544, an oral G12V-preferring, dual ON/OFF state, multi-KRAS inhibitor: Radnor, Pennsylvania Friday, January 10, 2025 ...

Additionally, the Phase 1 clinical trial evaluating QTX3034, an oral G12D-preferring multi-KRAS inhibitor, as a monotherapy and in combination with cetuximab, continues to enroll patients, and data is ...

Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics as a new category in regenerative medicine, today announced that it has closed a US$115 million ...

Janux Therapeutics has a robust balance sheet, with $658.1 million in liquid assets and no debt. See why I reiterate my buy ...

High Q Technologies today announced the commercial availability and first sale of FATHOM, a class-leading and innovative EPR ...

Acellera Therapeutics, a pioneer in computational chemistry and AI-driven drug discovery, today announced the launch of ...

QTX-3046 is under clinical development by Quanta Therapeutics and currently in Phase I for Lung Cancer. According to GlobalData, Phase I drugs for Lung Cancer have a 78% phase tra ...

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) traded down 3.7% during trading on Friday . The company traded as low ...

Verve Therapeutics, Inc. (NASDAQ:VERV – Get Free Report)’s share price was up 6.2% during trading on Friday . The company traded as high as $6.40 and last traded at $6.38. Approximately 98,868 shares ...

The business fields of quantum computing and AI are seen as the next frontier ... company focused on the development of new and effective cannabinoid therapeutics. The Company conducts medical ...